IL163846A0 - Multiple-component solid phases containing at least one active pharmaceutical ingredient - Google Patents
Multiple-component solid phases containing at least one active pharmaceutical ingredientInfo
- Publication number
- IL163846A0 IL163846A0 IL16384603A IL16384603A IL163846A0 IL 163846 A0 IL163846 A0 IL 163846A0 IL 16384603 A IL16384603 A IL 16384603A IL 16384603 A IL16384603 A IL 16384603A IL 163846 A0 IL163846 A0 IL 163846A0
- Authority
- IL
- Israel
- Prior art keywords
- active pharmaceutical
- pharmaceutical ingredient
- solid phases
- phases containing
- component solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/544—Diformyl benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/124—Acids containing four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/12—Saturated polycyclic compounds
- C07C61/125—Saturated polycyclic compounds having a carboxyl group bound to a condensed ring system
- C07C61/135—Saturated polycyclic compounds having a carboxyl group bound to a condensed ring system having three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/307—Monocyclic tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36076802P | 2002-03-01 | 2002-03-01 | |
PCT/US2003/006662 WO2003074474A2 (en) | 2002-03-01 | 2003-03-03 | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163846A0 true IL163846A0 (en) | 2005-12-18 |
Family
ID=27789020
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16384603A IL163846A0 (en) | 2002-03-01 | 2003-03-03 | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
IL163846A IL163846A (en) | 2002-03-01 | 2004-08-31 | Solid phases with multiple ingredients and at least one pharmaceutical substance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL163846A IL163846A (en) | 2002-03-01 | 2004-08-31 | Solid phases with multiple ingredients and at least one pharmaceutical substance |
Country Status (7)
Country | Link |
---|---|
US (4) | US20030224006A1 (xx) |
EP (1) | EP1494998A2 (xx) |
JP (3) | JP4906233B2 (xx) |
AU (1) | AU2003213719A1 (xx) |
CA (1) | CA2477923C (xx) |
IL (2) | IL163846A0 (xx) |
WO (1) | WO2003074474A2 (xx) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003101392A2 (en) | 2002-05-31 | 2003-12-11 | Transform Pharmaceuticals, Inc. | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US20030224006A1 (en) | 2002-03-01 | 2003-12-04 | Zaworotko Michael J. | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
WO2004078163A2 (en) * | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2006500377A (ja) | 2002-06-21 | 2006-01-05 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 改善された溶解性を有する医薬組成物 |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP1596869B1 (en) * | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
ATE550022T1 (de) * | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
WO2004102151A2 (en) * | 2003-05-06 | 2004-11-25 | New Century Pharmaceuticals | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties |
US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
MXPA06002507A (es) * | 2003-09-04 | 2006-06-20 | Cephalon Inc | Composiciones de modafinil. |
US20070043509A1 (en) * | 2003-11-03 | 2007-02-22 | Carter Daniel C | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
JP2007516259A (ja) * | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US20090018202A1 (en) | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
WO2005092884A1 (en) * | 2004-02-26 | 2005-10-06 | Transform Pharmaceuticals, Inc. | Novel crystalline forms of conazoles and methods of making and using the same |
US20070287194A1 (en) | 2004-03-12 | 2007-12-13 | S.S.C.I., Inc | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound |
WO2006007448A2 (en) * | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
US20080319068A1 (en) * | 2005-04-27 | 2008-12-25 | Transform Pharmaceuticals, Inc. | Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same |
US20070099237A1 (en) * | 2005-10-31 | 2007-05-03 | The Regents Of The University Of Michigan | Reaction co-crystallization of molecular complexes or co-crystals |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
WO2008035960A2 (en) * | 2006-09-21 | 2008-03-27 | Avantium International B.V. | Method for the preparation of a co-crystal |
EP2094649A2 (en) * | 2006-11-02 | 2009-09-02 | University of South Florida | Materials and methods for co-crystal controlled solid-state synthesis of imides and imines |
US7544830B2 (en) | 2007-01-10 | 2009-06-09 | The University Of Connecticut | Methods and systems for alkyl ester production |
TW200901889A (en) * | 2007-02-09 | 2009-01-16 | Basf Se | Crystalline complexes of agriculturally active organic compounds |
KR20090115970A (ko) * | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
WO2008108639A1 (en) * | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
US8471044B2 (en) * | 2007-06-06 | 2013-06-25 | University Of South Florida | Epigallocatechin-3-gallate crystal compositions |
WO2008153945A2 (en) | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
GB0813709D0 (en) * | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
US8236787B2 (en) | 2008-12-09 | 2012-08-07 | Synthonics, Inc. | Frequency modulated drug delivery (FMDD) |
EP2400848A4 (en) | 2009-02-26 | 2012-07-25 | Thar Pharmaceuticals Inc | CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS |
JP5558875B2 (ja) * | 2009-03-19 | 2014-07-23 | 日本曹達株式会社 | 新規包接錯体、エポキシ樹脂組成物及び半導体封止用エポキシ樹脂組成物 |
WO2010112411A1 (en) * | 2009-03-30 | 2010-10-07 | Tibotec Pharmaceuticals | Co-crystal of etravirine and nicotinamide |
US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
CN102060755B (zh) * | 2010-12-28 | 2012-08-22 | 吉林大学 | 一种对乙酰氨基酚药物共晶及其制备方法 |
CN102060777B (zh) * | 2010-12-28 | 2012-11-21 | 吉林大学 | 苯妥英药物共晶及其制备方法 |
CA2831086A1 (en) | 2011-03-24 | 2012-09-27 | University Of South Florida | Lithium compositions |
RU2655435C2 (ru) * | 2013-07-25 | 2018-05-29 | Басф Се | Соли дасатиниба в аморфной форме |
AU2014295144B2 (en) * | 2013-07-25 | 2017-06-15 | Basf Se | Salts of Dasatinib in crystalline form |
US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
CN113754634A (zh) | 2014-05-27 | 2021-12-07 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体络合物 |
US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
KR102618114B1 (ko) | 2015-04-02 | 2023-12-27 | 라티오팜 게엠베하 | 이브루티닙과 카복실산의 공결정체 |
KR20180008594A (ko) * | 2015-05-18 | 2018-01-24 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 및 그의 용도 |
EP3302447A4 (en) * | 2015-06-05 | 2019-02-27 | The Regents of The University of Michigan | METHOD FOR IMPROVING BIOAVAILABILITY OF SMALL ORGANIC MOLECULES AND DEPOSITED FILMS MADE THEREFROM |
US10500218B2 (en) * | 2015-11-15 | 2019-12-10 | Northwestern University | Uptake of pharmaceuticals within cyclodextrin-based porous materials |
WO2017089931A1 (en) | 2015-11-25 | 2017-06-01 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
CN106823442A (zh) * | 2017-03-08 | 2017-06-13 | 福建三农化学农药有限责任公司 | 一种全氟辛酸的回收方法和系统 |
EP3681865A1 (en) | 2017-09-05 | 2020-07-22 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
US20230338300A1 (en) * | 2020-08-14 | 2023-10-26 | Board Of Regents, The University Of Texas System | Pharmaceutical composition containing cocrystals for additive manufacturing |
Family Cites Families (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2711411A (en) * | 1955-06-21 | B-bromotheophylijne salt of z-amino-z- | ||
US2554816A (en) | 1950-04-04 | 1951-05-29 | American Cyanamid Co | Heterocyclic sulfonamides and methods of preparation thereof |
US2665277A (en) * | 1950-10-17 | 1954-01-05 | Mallinckrodt Chemical Works | Monobasic morphine phosphate hemihydrate and process of preparing same |
US2980679A (en) | 1957-04-04 | 1961-04-18 | Omikron Gagliardi Societa Di F | Process for preparing heterocyclic sulfonamides |
US3020420A (en) * | 1959-06-24 | 1962-02-06 | Gen Electric | Limiter circuit employing shunt diode means to sweep out distributed capacitance in the non-conducting state |
US3028420A (en) | 1959-06-26 | 1962-04-03 | British Drug Houses Ltd | Compound of betaine and chloral and method for preparing same |
JPS4633588Y1 (xx) | 1967-11-30 | 1971-11-19 | ||
GB1297261A (xx) * | 1969-01-13 | 1972-11-22 | ||
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3664858A (en) * | 1970-02-18 | 1972-05-23 | Minnesota Mining & Mfg | Heat-sensitive copy-sheet |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3970651A (en) * | 1974-01-07 | 1976-07-20 | Bristol-Myers Company | Crystalline cephalosporin derivative |
JPS5842168B2 (ja) * | 1974-12-20 | 1983-09-17 | トウコウヤクヒンコウギヨウ カブシキガイシヤ | 局所用剤の製造方法 |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5416494A (en) | 1977-07-08 | 1979-02-07 | Yamanouchi Pharmaceut Co Ltd | Complexes of crown ether with sulfonamides |
JPS5495589A (en) | 1977-12-30 | 1979-07-28 | Sumitomo Chem Co Ltd | Production of cephalosporin derivative |
US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4198507A (en) * | 1978-11-13 | 1980-04-15 | Hoffmann-La Roche Inc. | Theophylline magnesium salicylate |
US4368197A (en) * | 1979-02-21 | 1983-01-11 | Research Corporation | Zinc aminophylline and its use in the treatment of bronchospasms |
DE3064400D1 (en) * | 1979-07-05 | 1983-09-01 | Procter & Gamble | Dehydrated amino acid food additives, their preparation and use in foodstuffs |
JPS572367A (en) * | 1980-06-07 | 1982-01-07 | Kansai Paint Co Ltd | Water-dispersed thermosetting resin slurry paint composition |
DE3024158A1 (de) * | 1980-06-27 | 1982-01-28 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung waermehaertender, mit wasser verduennbarer lacke fuer die beschichtung metallischer substrate |
US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
DE3365679D1 (en) * | 1982-10-21 | 1986-10-02 | Ici Plc | Method of thickening aqueous latex compositions |
LU84515A1 (fr) * | 1982-12-09 | 1984-10-22 | Oreal | Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
GB8500862D0 (en) | 1985-01-14 | 1985-02-20 | Tate & Lyle Plc | Composition |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
NZ223799A (en) | 1987-03-25 | 1989-12-21 | Janssen Pharmaceutica Nv | Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions |
US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
US4792569A (en) | 1987-08-27 | 1988-12-20 | Mcneilab, Inc. | Anticonvulsant phenethyl sulfamates |
JP2581707B2 (ja) | 1987-10-02 | 1997-02-12 | 科研製薬株式会社 | 抗真菌剤組成物 |
US5006513A (en) * | 1987-11-09 | 1991-04-09 | Miles Inc. | Antimycotic compositions of nikkomycin compounds and azole antimycotica |
US5023092A (en) * | 1988-06-16 | 1991-06-11 | Ici Americas Inc. | Mannitol having gamma sorbitol polymorph |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US4925674A (en) * | 1988-08-25 | 1990-05-15 | Himedics, Inc. | Amoxicillin microencapsulated granules |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5190583A (en) * | 1989-12-04 | 1993-03-02 | Transfer-Electric Gesellschaft Fur | Aqueous coating composition and the use thereof for coating to be protected from light, especially ultraviolet radiation |
US4994604A (en) * | 1990-01-10 | 1991-02-19 | Merck & Co., Inc. | Formation and resolution of ibuprofen lysinate |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5177262A (en) * | 1991-07-19 | 1993-01-05 | Polaroid Corporation | Process and composition for use in photographic materials containing hydroquinones |
AU651244B2 (en) | 1991-09-19 | 1994-07-14 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
DK0631578T3 (da) | 1992-03-18 | 2001-08-27 | Janssen Pharmaceutica Nv | Itraconazol- og saperconazol-stereoisomerer |
US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5258402A (en) | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
US5380867A (en) * | 1992-12-02 | 1995-01-10 | Hoechst Celanese Corporation | Selective precipitation of α-aryl carboxylic acid salts |
US5332834A (en) * | 1992-12-02 | 1994-07-26 | Hoechst Celanese Corporation | Racemization of an enantomerically enriched α-aryl carboxylic acid |
US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US5414997A (en) * | 1993-01-11 | 1995-05-16 | Tailer; Peter L. | Thermal lag machine |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
EP0680324A4 (en) | 1993-01-27 | 1996-04-10 | Sepracor Inc | METHODS AND COMPOSITIONS USING (2R, 4S) ITRACONAZOLE. |
IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
US5412094A (en) * | 1993-06-28 | 1995-05-02 | Eli Lilly And Company | Bicyclic beta-lactam/paraben complexes |
TW349870B (en) * | 1993-09-30 | 1999-01-11 | Janssen Pharmaceutica Nv | An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof |
US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
RO118291B1 (ro) | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
HU225062B1 (en) | 1993-12-21 | 2006-05-29 | Schering Corp | Tetrahydrofuran derivatives with antifungal- effect, pharmaceutical compositions containing them and process for their preparation |
GB9404248D0 (en) | 1994-03-05 | 1994-04-20 | Boots Co Plc | Pharmaceutical formulations |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
FI944182A (fi) | 1994-09-09 | 1996-03-10 | Xyrofin Oy | Yhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö |
ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5523090A (en) * | 1995-02-24 | 1996-06-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin treatment composition |
US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
US5614342A (en) * | 1995-05-02 | 1997-03-25 | Eastman Kodak Company | Methods for preparing cocrystals of titanyl fluorophthalocyanines and unsubstituted titanyl phthalocyanine, electrophotographic elements, and titanyl phthalocyanine compositions |
US6001996A (en) | 1995-05-11 | 1999-12-14 | Eli Lilly And Company | Complexes of cephalosporins and carbacephalosporins with parabens |
US5780058A (en) | 1995-07-21 | 1998-07-14 | Alza Corporation | Oral delivery of discrete units |
US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
US5952187A (en) | 1995-12-01 | 1999-09-14 | Oxis International, Inc. | Topiramate immunoassay |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US5635535A (en) * | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
ES2311571T3 (es) * | 1996-04-12 | 2009-02-16 | G.D. Searle Llc | Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2. |
EP0915697B1 (en) * | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
US5994365A (en) | 1997-02-25 | 1999-11-30 | Diazans Limited | Substituted diazaanthracene compounds having pharmaceutical utility |
CA2232855C (en) * | 1997-04-10 | 2007-10-09 | Roche Consumer Health (Worldwide) Sa | Pharmaceutical formulation |
KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
KR19990001564A (ko) | 1997-06-16 | 1999-01-15 | 유충식 | 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제 |
US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
JP4215188B2 (ja) * | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | 薬剤供給を調節するデバイスのための速度調節膜 |
CA2316976C (en) * | 1997-12-29 | 2009-02-17 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
DK1051217T3 (da) | 1997-12-31 | 2003-12-08 | Eckenhoff Bonnie J | System til kontrol af osmotisk medikamentlevering |
JP2002507511A (ja) | 1998-01-21 | 2002-03-12 | リフレキサイト・コーポレーション | 長寿命ポリ塩化ビニル蛍光シ−ト材 |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
IT1303251B1 (it) | 1998-10-26 | 2000-11-06 | Ind Chimica Srl | Processo industriale per la purificazione di 2',3'- dideidro-3'-deossitimidina. |
ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
EP1126827A2 (en) * | 1998-11-02 | 2001-08-29 | Alza Corporation | Controlled delivery of active agents |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
WO2000042021A1 (en) | 1999-01-14 | 2000-07-20 | Merck Frosst Canada & Co. | Synthesis of 4-[(5-substituted or unsubstituted phenyl) -3-substituted -1h-pyrazol -1-yl] benzenesulfonamides |
ATE279921T1 (de) | 1999-01-19 | 2004-11-15 | Ortho Mcneil Pharm Inc | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache |
JP2002537326A (ja) | 1999-02-24 | 2002-11-05 | ユニヴァーシティ・オブ・シンシナティ | 衝動調節障害の治療のためのスルファメート誘導体の使用 |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
EP1034826A1 (en) * | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
JP4825353B2 (ja) * | 1999-04-08 | 2011-11-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 血圧を下げることに有用な抗痙攣薬誘導体 |
MXPA01012187A (es) | 1999-05-28 | 2002-06-21 | Jeffrey Berlant | Compuestos y metodos para el tratamiento del trastorno por estres postraumatico. |
US6413965B1 (en) * | 1999-06-30 | 2002-07-02 | Pfizer Inc. | Compositions and treatment for diabetic complications |
SK286621B6 (sk) | 1999-08-20 | 2009-02-05 | Ortho-Mcneil Pharmaceutical, Inc. | Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva |
US6268385B1 (en) * | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
EP1212051A4 (en) * | 1999-08-27 | 2004-03-31 | Merck & Co Inc | METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
AU784490B2 (en) | 1999-12-08 | 2006-04-13 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
PT1150960E (pt) | 1999-12-08 | 2005-06-30 | Pharmacia Corp | Formas cristalinas polimorficas do celecoxib |
EP1150959B1 (en) * | 1999-12-08 | 2008-02-27 | Pharmacia Corporation | Solid-state form of celecoxib having enhanced bioavailability |
BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
US6376616B1 (en) * | 1999-12-20 | 2002-04-23 | Basf Corporation | Pigment dispersants having anionic functionality for use in anodic electrocoat compositions |
MY127898A (en) | 1999-12-22 | 2006-12-29 | Pharmacia Corp | Dual-release compositions of a cyclooxygenase-2 inhibitor |
CA2394222A1 (en) * | 1999-12-22 | 2001-06-28 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
US6348458B1 (en) * | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
JP2003519698A (ja) | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
EP1120109A3 (en) * | 2000-01-24 | 2002-07-10 | Pfizer Products Inc. | Rapidly disintegrating and fast dissolving solid dosage form |
EP1274425A1 (en) | 2000-04-18 | 2003-01-15 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
GB0015239D0 (en) | 2000-06-21 | 2000-08-16 | Biochemie Gmbh | Organic compounds |
TR200001872A3 (tr) | 2000-06-26 | 2002-01-21 | Fako Ilaclari A.S | 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem. |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
CA2416792C (en) | 2000-07-27 | 2010-02-09 | Teva Pharmaceutical Industries Ltd. | Crystalline and pure modafinil, and process of preparing the same |
US20020119193A1 (en) | 2000-08-18 | 2002-08-29 | Le Trang T. | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
DE60120710T2 (de) * | 2000-08-18 | 2007-06-14 | Pharmacia Corp. | Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib |
US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US6663897B2 (en) | 2001-02-06 | 2003-12-16 | Dsm Ip Assets B.V. | Oral itraconazole formulations and methods of making the same |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
PL205828B1 (pl) | 2001-06-28 | 2010-05-31 | Sumitomo Chemical Co | Sposób wytwarzania 1,2-dichloroetanu |
UA78211C2 (en) * | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
US7429238B2 (en) | 2001-10-15 | 2008-09-30 | The Regents Of The University Of Michigan | Systems and methods for the generation of crystalline polymorphs |
CA2363376A1 (en) * | 2001-11-16 | 2003-05-16 | Bernard Charles Sherman | Solid pharmaceutical compositions for oral administration comprising itraconazole |
GB0203306D0 (en) | 2002-02-12 | 2002-03-27 | Norferm Da | Method |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2003101392A2 (en) | 2002-05-31 | 2003-12-11 | Transform Pharmaceuticals, Inc. | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
US20030224006A1 (en) | 2002-03-01 | 2003-12-04 | Zaworotko Michael J. | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
WO2004089313A2 (en) | 2003-04-01 | 2004-10-21 | Transform Pharmaceuticals, Inc. | Novel olanzapine forms and related methods of treatment |
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
EP1364649A1 (en) | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2006500377A (ja) * | 2002-06-21 | 2006-01-05 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 改善された溶解性を有する医薬組成物 |
US7033715B2 (en) * | 2002-12-02 | 2006-04-25 | Eastman Kodak Company | Uniform cocrystals of titanyl fluorophthalocyanine and titanyl phthalocyanine formed in trichloroethane, and charge generating layer containing same |
US7033716B2 (en) * | 2002-12-02 | 2006-04-25 | Eastman Kodak Company | Two-stage milling process for preparing cocrystals of titanyl fluorophthalocyanine and titanyl phthalocyanine, and electrophotographic element containing same |
US6949139B2 (en) * | 2002-12-02 | 2005-09-27 | Eastman Kodak Company | Process for forming cocrystals containing chlorine-free titanyl phthalocyanines and low concentration of titanyl fluorophthalocyanine using organic milling aid |
PL377351A1 (pl) | 2002-12-13 | 2006-01-23 | Cilag Ag | Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
EP1596869B1 (en) | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
ATE550022T1 (de) | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
US6913830B2 (en) * | 2003-08-14 | 2005-07-05 | Ppg Industries Ohio, Inc. | Coating compositions containing semiconductor colorants |
US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
MXPA06002507A (es) | 2003-09-04 | 2006-06-20 | Cephalon Inc | Composiciones de modafinil. |
JP2007510136A (ja) | 2003-10-06 | 2007-04-19 | ソルヴィーアス アクチェンゲゼルシャフト | 分子状固体の結晶形態を並行検出する方法 |
JP4994039B2 (ja) | 2003-11-26 | 2012-08-08 | スパーナス ファーマシューティカルズ インコーポレイテッド | 脂溶性または疎水性化合物の送達に有用なミセル系 |
JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
EP2343073A3 (en) | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
WO2005070938A1 (en) | 2004-01-27 | 2005-08-04 | Synthon B.V. | Stable salts of olanzapine |
AU2005212229B2 (en) | 2004-02-06 | 2011-06-09 | Cephalon, Inc. | Modafinil compositions |
US20070287194A1 (en) | 2004-03-12 | 2007-12-13 | S.S.C.I., Inc | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound |
SG151299A1 (en) | 2004-03-25 | 2009-04-30 | Univ Michigan | Gossypol co-crystals and the use thereof |
WO2005118577A1 (en) | 2004-04-22 | 2005-12-15 | Transform Pharmaceuticals, Inc. | Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US20050252649A1 (en) | 2004-05-11 | 2005-11-17 | Ming-Chi Chiu | Leadless lower temperature co-crystal phase transition metal heat conductive device |
US7145005B2 (en) | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
WO2006007448A2 (en) * | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
US7259869B2 (en) * | 2004-06-29 | 2007-08-21 | Kla-Tencor Technologies Corporation | System and method for performing bright field and dark field optical inspection |
WO2006024930A1 (en) | 2004-09-01 | 2006-03-09 | Pharmacia & Upjohn Company Llc | Novel co-crystals between polyethylene glycols and 5-phenylpyrazolyl-1-benzenesulfonamides |
US20080319068A1 (en) | 2005-04-27 | 2008-12-25 | Transform Pharmaceuticals, Inc. | Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same |
JP4633588B2 (ja) | 2005-09-20 | 2011-02-16 | Kddi株式会社 | 気象データ配信装置および局域気象データ配信システムならびに同システムにおける気象データ推定方法 |
-
2003
- 2003-03-03 US US10/378,956 patent/US20030224006A1/en not_active Abandoned
- 2003-03-03 JP JP2003572946A patent/JP4906233B2/ja not_active Expired - Fee Related
- 2003-03-03 AU AU2003213719A patent/AU2003213719A1/en not_active Abandoned
- 2003-03-03 EP EP03711407A patent/EP1494998A2/en not_active Ceased
- 2003-03-03 WO PCT/US2003/006662 patent/WO2003074474A2/en active Application Filing
- 2003-03-03 IL IL16384603A patent/IL163846A0/xx unknown
- 2003-03-03 CA CA2477923A patent/CA2477923C/en not_active Expired - Lifetime
-
2004
- 2004-08-31 IL IL163846A patent/IL163846A/en not_active IP Right Cessation
-
2010
- 2010-04-08 JP JP2010089773A patent/JP2010180239A/ja active Pending
-
2011
- 2011-09-08 JP JP2011195630A patent/JP2012031180A/ja active Pending
-
2014
- 2014-02-13 US US14/179,862 patent/US10633344B2/en not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/639,223 patent/US20170362182A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/270,981 patent/US20190169130A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003074474A3 (en) | 2003-12-18 |
US10633344B2 (en) | 2020-04-28 |
CA2477923A1 (en) | 2003-09-12 |
US20190169130A1 (en) | 2019-06-06 |
JP4906233B2 (ja) | 2012-03-28 |
WO2003074474A2 (en) | 2003-09-12 |
US20030224006A1 (en) | 2003-12-04 |
JP2005519112A (ja) | 2005-06-30 |
JP2010180239A (ja) | 2010-08-19 |
AU2003213719A8 (en) | 2003-09-16 |
CA2477923C (en) | 2021-02-23 |
AU2003213719A1 (en) | 2003-09-16 |
IL163846A (en) | 2015-07-30 |
JP2012031180A (ja) | 2012-02-16 |
EP1494998A2 (en) | 2005-01-12 |
US20140162989A1 (en) | 2014-06-12 |
US20170362182A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163846A0 (en) | Multiple-component solid phases containing at least one active pharmaceutical ingredient | |
GB0210397D0 (en) | Pharmaceutical formulations | |
PL372084A1 (en) | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | |
IL166286A0 (en) | Multicomponent pharmaceutical dosage form | |
IL161940A0 (en) | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | |
HUP0501186A2 (en) | Pharmaceutical compositions comprising active vitamin d compounds | |
GB0218625D0 (en) | Pharmaceutical compounds | |
PT1362582E (pt) | Forma de dosagem sólida revestida | |
GB0102342D0 (en) | Pharmaceutical formulation | |
IL164699A0 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
GB0118689D0 (en) | Pharmaceutical formulation | |
AU2003250372A8 (en) | Pharmaceutical composition | |
PL366432A1 (en) | Pharmaceutical formulation | |
GB0215775D0 (en) | Pharmaceutical compounds | |
HUP0303948A2 (hu) | Szájban diszpergálódó szilárd gyógyszerforma | |
GB2392093B (en) | Pharmaceutical formulations | |
GB0206505D0 (en) | Pharmaceutical combination | |
EP1480649A4 (en) | STABLE PHARMACEUTICAL COMPOSITIONS | |
PL373409A1 (en) | Pharmaceutical combination | |
GB0225926D0 (en) | Pharmaceutical paste formulations | |
GB0104749D0 (en) | Pharmaceutical formulation | |
AU2003238900A8 (en) | Pharmaceutical formulation | |
GB0225041D0 (en) | Pharmaceutical formulation | |
ZA200500409B (en) | Multicomponent pharmaceutical dosage form | |
GB0210240D0 (en) | Pharmaceutical combination |